Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other Working Capital Changes (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other Working Capital Changes for 16 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 260.25% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 230.75% year-over-year, with the annual reading at $1.7 million for FY2025, 230.75% up from the prior year.
  • Other Working Capital Changes hit $2.3 million in Q4 2025 for Ligand Pharmaceuticals, up from -$2.3 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $15.3 million in Q3 2021 to a low of -$8.9 million in Q2 2021.
  • Historically, Other Working Capital Changes has averaged $153650.0 across 5 years, with a median of $672500.0 in 2023.
  • Biggest five-year swings in Other Working Capital Changes: plummeted 752.5% in 2023 and later surged 1614.52% in 2024.
  • Year by year, Other Working Capital Changes stood at $914000.0 in 2021, then surged by 506.89% to $5.5 million in 2022, then crashed by 90.55% to $524000.0 in 2023, then crashed by 369.85% to -$1.4 million in 2024, then skyrocketed by 260.25% to $2.3 million in 2025.
  • Business Quant data shows Other Working Capital Changes for LGNDZ at $2.3 million in Q4 2025, -$2.3 million in Q3 2025, and $821000.0 in Q2 2025.